[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endometritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endometritis":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,55,85],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":35,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100644230","phase-4-cyclobenzaprine-for-postoperative-pain-in-minimally-invasive-hysterectomy-100644230",false,"NCT07664956","Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy","Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age \\>18yo\n* Female\n* English speaking\n* Undergoing (robotic assisted or classic) total laparoscopic hysterectomy ± unilateral or bilateral salpingectomy ± unilateral or bilateral oophorectomy\n* If other procedures such as lysis of adhesions, excision of endometriosis, or ureterolysis are indicated based on intraoperative evaluation, those patients may still be included\n* Surgery took place at ChristianaCare Hospitals\n* No allergies or contraindications to standard of care post operative pain medications (acetaminophen, NSAIDs, narcotics) or cyclobenzaprine\n\nExclusion Criteria:\n\n* Age \\\u003C18yo\n* Male\n* Pregnant, breastfeeding\n* Non-English speaking\n* Primary procedures other than laparoscopic hysterectomy\n* Laparoscopic myomectomy\n* Laparoscopic resection of endometriosis\n* Laparoscopic unilateral or bilateral salpingectomy ± unilateral or bilateral oophorectomy ± unilateral or bilateral cystectomy without hysterectomy\n* Hysteroscopic procedures\n* Bartholin gland marsupialization\n* Operations that are scheduled as or converted to the open approach\n* Procedures with planned or unplanned bladder or bowel surgery\n* Allergies or contraindications to standard post operative pain control medications (acetaminophen, NSAIDs, narcotics), such as kidney or liver damage\u002Ffailure, bariatric surgery, history of gastric ulcer, etc.\n* Chronic pain issues, whether self-diagnosed or by a physician, currently undergoing management\n* Currently undergoing medication assisted treatment for opioid use disorder\n* Currently using opioids consistently\n* Allergies or contraindications to cyclobenzaprine:\n* Absolute: use of MAO inhibitors within 14 days, recent heart attack, congestive heart failure, heart block or other conduction abnormalities, cardiac arrhythmias, hyperthyroidism, history of serotonin syndrome\n* Allergies or contraindications to inactive ingredients in Flexeril, such as lactose\n* Patient's receiving gabapentin at baseline or postoperatively, due to potential sedating effects, or other sedating drugs such as scheduled benzodiazepines and barbiturates","FEMALE","18 Years",{"count":19,"type":20},36,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","Typical postoperative pain control after minimally invasive hysterectomy includes ibuprofen, acetaminophen, and a short course of narcotics. The purpose of this study is to see if adding cyclobenzaprine to this regime improves pain control and lessens narcotic use.",[26,27,28,29,30,31,32,33,34],"Minimally Invasive Surgical Procedures","Abnormal Uterine Bleeding, Unspecified","Adenomyosis of Uterus","Fibroid Uterus","Chronic Pelvic Pain","Endometriosis","Menorrhagia","Endometritis","Adnexal Diseases",[36,37,38,39,40,41],"cyclobenzaprine","flexeril","hysterectomy","minimally invasive hysterectomy","pain control","multimodal pain control","NOT_YET_RECRUITING","2026-06-18",{"date":45,"type":46},"2026-06-24","ACTUAL",{"date":48,"type":20},"2026-07-01",{"date":50,"type":20},"2026-12-01",{"name":52,"class":53},"Christiana Care Health Services","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":63,"enrollmentInfo":64,"targetDuration":66,"studyType":67,"phases":4,"briefSummary":68,"conditions":69,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":84},"100640629","fertility-outcomes-after-antibiotic-treatment-in-women-with-chronic-endometritis-100640629","NCT07603492","Fertility Outcomes After Antibiotic Treatment In Women With Chronic Endometritis","Monitoring of Reproductive Outcomes in Women With Chronic Endometritis: A Prospective Cohort Study on the Impact of Antibiotic Treatment on Fertility and Obstetric Outcomes","MORE","Inclusion Criteria\n\n* Female participants aged 18-40 years.\n* Diagnosis of infertility (primary or secondary infertility).\n* Indication for diagnostic hysteroscopy with endometrial biopsy as part of infertility evaluation.\n* Suspected or confirmed chronic endometritis.\n* Ability and willingness to provide written informed consent prior to any study-related procedures.\n* Willingness to undergo protocol-defined antibiotic treatment.\n* Willingness to comply with study procedures and follow-up assessments.\n* Agreement to reproductive outcome monitoring following treatment, including spontaneous conception and pregnancies achieved through assisted reproductive technologies (ART).\n\nExclusion Criteria\n\n* Age \\>40 years.\n* Current pregnancy.\n* Known hypersensitivity or contraindication to tetracycline antibiotics or other study-related antibiotic therapy without a suitable alternative treatment option.\n* Severe systemic disease or medical condition that, in the opinion of the investigator, could interfere with study participation, safety, or interpretation of study results.\n* Active malignant disease requiring systemic treatment.\n* HIV infection or other severe immunodeficiency disorder.\n* Acute pelvic inflammatory disease or clinically significant active genital tract infection requiring immediate treatment.\n* Previous participation in this study.\n* Inability to undergo planned hysteroscopy or endometrial biopsy.\n* Inability or unwillingness to comply with study procedures or follow-up requirements.\n* Failure or refusal to provide written informed consent.","40 Years",{"count":65,"type":20},100,"2 Years","OBSERVATIONAL","Chronic endometritis (CE) is a long-lasting inflammation of the lining of the uterus. Many women with CE do not have symptoms, but the condition may affect fertility, embryo implantation, and pregnancy outcomes. CE is usually diagnosed during hysteroscopy, a procedure that allows doctors to look inside the uterus and collect a small tissue sample for laboratory testing.\n\nThe goal of this prospective cohort study is to learn how common CE is in women with infertility and to determine whether antibiotic treatment improves reproductive outcomes. The study will also examine whether hysteroscopic findings match laboratory-confirmed CE and whether certain findings can help doctors diagnose CE more accurately. In addition, researchers will study the types of bacteria found in the uterine lining and their possible relationship to fertility and pregnancy outcomes.\n\nThe main questions the study aims to answer are:\n\n* How common is chronic endometritis in women undergoing infertility evaluation?\n* Does antibiotic treatment improve fertility and pregnancy outcomes in women with CE?\n* Can hysteroscopic findings reliably predict CE confirmed by laboratory testing?\n* Are specific bacteria associated with poorer reproductive outcomes? Researchers will enroll approximately 100 women aged 18 to 40 years with diagnosed infertility who are scheduled for hysteroscopy and endometrial biopsy as part of infertility evaluation. Participants with severe systemic disease, pregnancy, inability to undergo hysteroscopy or antibiotic treatment, or allergy to study antibiotics without a suitable alternative will not be included.\n\nParticipants will:\n\n* Undergo diagnostic hysteroscopy and endometrial biopsy\n* Have tissue samples examined using histopathology and immunohistochemistry to identify CE\n* Receive standardized antibiotic treatment if CE is confirmed\n* Be followed for up to 12 months after treatment to monitor fertility outcomes\n* Continue follow-up during pregnancy, if pregnancy occurs, to assess pregnancy and delivery outcomes Researchers will evaluate spontaneous pregnancies, embryo transfer success, implantation rates, miscarriage rates, time to pregnancy, and live birth outcomes. Pregnancy complications such as preeclampsia, placental disorders, premature rupture of membranes, and preterm birth will also be recorded.\n\nThe study is expected to run from January 2026 through December 2029. Data collected during the study may help improve the diagnosis and treatment of chronic endometritis in women with infertility and may support better reproductive outcomes in clinical practice.",[33,70,71,72],"Infertility","Hysteroscopy","Pregnancy Disease","RECRUITING","2026-05-22",{"date":76,"type":46},"2026-05-27",{"date":78,"type":46},"2026-01-01",{"date":80,"type":20},"2030-01-01",{"name":82,"class":83},"Faculty Hospital Kralovske Vinohrady","OTHER_GOV",2,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":21,"phases":95,"briefSummary":97,"conditions":98,"keywords":104,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":54},"100613355","study-of-endometrial-immune-and-microbiological-modifications-in-cases-of-recurrent-implantation-failure-andor-recurrent-pregnancy-loss-100613355","NCT07265505","Study of Endometrial Immune and Microbiological Modifications in Cases of Recurrent Implantation Failure and\u002For Recurrent Pregnancy Loss","Study of Immune and Microbiological Modifications of the Endometrium in Cases of Recurrent Implantation Failure and\u002For Recurrent Pregnancy Loss","IMERR","Inclusion Criteria:\n\n* Female aged ≥18 and \\\u003C36 years\n* Undergoing assisted reproductive technology (ART) in a fertility center\n* Covered by the French national health insurance system\n* Belonging to one of two groups:\n\n  * Study group: history of recurrent implantation failure (RIF) and\u002For recurrent pregnancy loss (RPL)\n  * Control group: no history of RIF or RPL\n\nExclusion Criteria:\n\n* Pregnant at inclusion\n* Refusal to provide written informed consent\n* Antibiotic use within one month prior to endometrial biopsy Positive serology for hepatitis B, hepatitis C or HIV\n* Uterine anatomical abnormalities (e.g., polyps, cavity-distorting fibroids, untreated hydrosalpinx)\n* Known chromosomal abnormality in either partner\n* Known autoimmune disease, thrombophilia, or antiphospholipid antibody syndrome\n* Persons under legal protection (e.g., guardianship, curatorship)","35 Years",{"count":65,"type":20},[96],"NA","The IMERR study aims to improve understanding of certain causes of infertility related to recurrent implantation failure (RIF) and\u002For recurrent pregnancy loss (RPL), conditions that affect many women undergoing assisted reproductive technology (ART). Despite medical advances, some patients repeatedly fail to achieve pregnancy, or experience repeated miscarriages. These situations may be linked to subtle immune or microbial disturbances in the uterus. This study seeks to identify immune and microbiological profiles in the endometrium during the implantation window-a crucial period when the embryo attaches to the uterine wall. We will compare women who have experienced RIF and\u002For RPL with women who have had no such history. Blood and uterine samples will be analyzed to investigate whether certain immune or microbial features are associated with these reproductive failures. The ultimate goal is to uncover predictive factors that may explain why some women experience implantation failure or pregnancy loss, and to lay the foundation for future personalized treatments to improve reproductive outcomes.",[99,100,101,102,33,31,103],"Recurrent Implantation Failure","Recurrent Pregnancy Loss","Infertility, Female","Endometrial Diseases","Adenomyosis",[105,106,70,107,108,109,110,111,112,103,31],"Uterine Immune Profile","Endometrial Receptivity","Recurrent Miscarriage","IVF Failure","Implantation Window","Reproductive Immunology","Endometrial Microbiome","Chronic Endometritis","2026-02-03",{"date":115,"type":46},"2026-02-05",{"date":117,"type":20},"2026-04",{"date":119,"type":20},"2031-04",{"name":121,"class":53},"Assistance Publique - Hôpitaux de Paris"]